Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Thorac Oncol. 2019 Nov;14(11):e257-e259. doi: 10.1016/j.jtho.2019.06.028.

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.

Author information

1
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Research Initiative for ALK-Related Malignancies, Cambridge, United Kingdom. Electronic address: geeta.geeta@unimib.it.
2
Department of Oncology, San Gerardo Hospital, Monza, Italy.
3
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
4
Haematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy.
5
Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
6
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Haematology and Clinical Research Unit, San Gerardo Hospital, Monza, Italy.
7
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Research Initiative for ALK-Related Malignancies, Haematology, Cambridge, United Kingdom and Clinical Research Unit, San Gerardo Hospital, Monza, Italy.
8
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; European Research Initiative for ALK-Related Malignancies.
PMID:
31668326
DOI:
10.1016/j.jtho.2019.06.028

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center